LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Expands Telehealth Reach for Zepbound Through Hims & Hers Platform
Hims & Hers expanded its platform functionality. Healthcare providers can now prescribe Eli Lilly’s weight-loss drug Zepbound in vials and KwikPen formats to...
Eli Lilly Shares Slide, Driven by CVS Medicare Obesity Model Exit
Eli Lilly shares fell as much as 3.8% after CVS Health opted out of a Medicare model for obesity medications. [7, 8] The decision threatens market penetration...
Eli Lilly acquires Kelonia for $7 billion, diversifying beyond obesity drugs
Eli Lilly and Company entered a definitive agreement to acquire clinical-stage biotechnology firm Kelonia Therapeutics. The deal includes an upfront payment of...
Eli Lilly nears Kelonia acquisition, targeting next-gen cancer gene therapy
Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics, a privately-held biotechnology firm. A formal announcement could occur as early as...
Eli Lilly’s Foundayo pill debuts with 1,390 prescriptions, boosting shares 2%
Eli Lilly’s oral weight-loss drug Foundayo recorded 1,390 prescriptions for the week ending April 10. Analysts estimate this total reflects only two days of...
Eli Lilly Faces FDA Safety Probe, Citing Obesity Drug Liver Risks
The U.S. Food and Drug Administration (FDA) requested additional data from Eli Lilly regarding potential liver injury risks for its new obesity treatment. This...
Eli Lilly buys CrossBridge Bio for $300M, boosting next-gen cancer pipeline
Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million. The deal adds dual-payload antibody-drug conjugates to Lilly’s oncology...
Eli Lilly reports Jaypirca success, meeting Phase 3 leukemia trial goals
Eli Lilly and Company reported positive topline results from its Phase 3 BRUIN CLL-322 trial for Jaypirca (pirtobrutinib). The study evaluated Jaypirca in...
Eli Lilly launches Foundayo oral pill, disrupting obesity market with $149 pricing
Eli Lilly released its once-daily oral weight-loss pill, Foundayo (orforglipron), in the United States. The medication targets adults with obesity or those who...
Eli Lilly target raised to $1,294, following FDA approval of Fundayo
BofA analyst Jason Gerberry raised the Eli Lilly (LLY) price target to $1,294. The previous price target for the pharmaceutical firm was $1,293. This revision...
Lilly's New Obesity Pill Launches Tomorrow — But Can It Justify a $935 Stock Price in a Price War With Novo?
Shares shifted as Eli Lilly secured FDA approval on April 1 for its once-daily weight-loss pill, the first oral obesity drug patients can take at any time...
Eli Lilly Wins FDA Approval for Foundayo, a Flexible Obesity Pill
The FDA approved Eli Lilly’s once-daily weight-loss pill, Foundayo (orforglipron), on April 1, 2026. This drug is the first oral GLP-1 for weight management...
Eli Lilly's $7.8 Billion Sleep-Drug Bet and AI Push: Is the GLP-1 Cash Machine Building a New Empire or Buying Growth It Cannot Organically Create?
Shares surged +3.3% to $950.30 as investors digested a one-two punch: a $7.8 billion deal to buy Centessa Pharmaceuticals and a $2.75 billion AI drug-discovery...
🟢 LLY is trading 3.3% up today amid a broad market rally on de-escalation hopes
LLY is trading at $950.30 (+3.32%) amid a broad market rally and de-escalation hopes in the Iran conflict. • The stock continues to see strength following...
🟢 LLY is trading 4% up today on news of acquiring Centessa Pharmaceuticals and expanding its AI drug discovery partnership
LLY is trading at $923.60 (+4.17%) following two significant company-specific announcements that overshadowed broader market trends. • Acquisition of Centessa...
Eli Lilly strikes $2.75B AI deal with Insilico for diabetes treatments
Eli Lilly has entered a strategic co-development partnership with Hong Kong-listed Insilico Medicine. The collaboration utilizes Insilico’s artificial...
Eli Lilly expands India manufacturing for Mounjaro, targeting surging GLP-1 demand
An analysis published March 24, 2026, details Eli Lilly’s major investment in India to boost manufacturing for its GLP-1 drug, tirzepatide. The expansion...
Eli Lilly to Discontinue Certain Insulin Products in Select European Countries
Eli Lilly is discontinuing specific insulin product presentations in selected countries. The European Medicines Agency (EMA) announced the move on March 23,...
Eli Lilly Secures Reassessment for Alzheimer's Drug Donanemab by UK Health Watchdog
The U.K.’s National Institute for Health and Care Excellence (NICE) will reevaluate Eli Lilly’s Alzheimer’s drug, donanemab, for National Health Service (NHS)...
RBC Capital Backs Eli Lilly, Citing Superior Retatrutide Weight Loss Potential
RBC Capital analyzed Eli Lilly’s Phase 3 retatrutide results on March 20, following the company's March 19 announcement. The firm reported that retatrutide...